Nuritas Leverages AI Platform to Identify Therapeutic Peptides for the Treatment of COVID-19
Excerpt from the article:
“CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nuritas, a biotechnology company that is revolutionizing the discovery and use of therapeutic peptides through artificial intelligence (AI) and genomics, today announced that it has received a grant from Partnership for Advanced Computing in Europe (PRACE) to identify therapeutic peptides for the treatment of patients with COVID-19. Under the terms of the grant, Nuritas will employ its proprietary AI platform to identify peptides with antiviral properties as well as peptides with cytokine regulatory properties, with the goal of creating a therapeutic ‘peptide cocktail.’ If successful, this approach has the potential to slow or stop disease progression by both mitigating viral replication and modifying the cytokine-based inflammatory response known to drive respiratory damage in patients with COVID-19.”
Click the button below to read the article:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?